Altamira Therapeutics Ltd. (CYTOF)
OTCMKTS · Delayed Price · Currency is USD
0.1053
0.00 (0.00%)
At close: Feb 5, 2026

Altamira Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Jun '25 Dec '24 Dec '23 Jan '23 Dec '21 Dec '20
Net Income
-5.65-8.46-4.31-27.78-18.71-9.27
Depreciation & Amortization
0.140.130.130.120.080.02
Asset Writedown & Restructuring Costs
---12.981.68-
Loss (Gain) on Equity Investments
1.070.770.04---
Stock-Based Compensation
0.540.530.420.361.320.42
Other Operating Activities
-0.850.881.521.50.283.01
Change in Accounts Receivable
-0.08-0.280.02-0.11-0.370.29
Change in Inventory
---0.360.87-0.92-
Change in Accounts Payable
0.190.06-3.671.323.22-0.2
Change in Other Net Operating Assets
0.350.24-0.711.65-1.730.25
Operating Cash Flow
-4.29-6.11-12.81-9.09-15-5.47
Capital Expenditures
-0.1-0.1----
Divestitures
-02.14---
Sale (Purchase) of Intangibles
----2.24-3.65-2.62
Investment in Securities
-0.02-0.02-0.53--0.2-
Other Investing Activities
0000-0
Investing Cash Flow
-0.12-0.121.61-2.24-3.84-2.62
Short-Term Debt Issued
--2.786.32-1.72
Total Debt Issued
0.44-2.786.32-1.72
Short-Term Debt Repaid
---1.49--0.05-
Long-Term Debt Repaid
--0.14-0.13-0.12-0.02-
Total Debt Repaid
-0.13-0.14-1.61-0.12-0.08-
Net Debt Issued (Repaid)
0.31-0.141.176.2-0.081.72
Issuance of Common Stock
4.737.3711.694.157.5118.17
Other Financing Activities
-0.68-0.73-1.04-0.06-0.18-0.72
Financing Cash Flow
4.366.5111.8210.37.2519.17
Foreign Exchange Rate Adjustments
-0.02-0.010.1-0.020.320.08
Net Cash Flow
-0.080.260.72-1.06-11.2711.16
Free Cash Flow
-4.4-6.22-12.81-9.09-15-5.47
Free Cash Flow Per Share
-1.02-2.19-26.08-199.68-452.91-364.11
Cash Interest Paid
0.020.010.170.020-
Levered Free Cash Flow
-2.1-3.46-10.04-2.64-7.79-5.03
Unlevered Free Cash Flow
-2.07-3.44-9.32-2.05-7.78-4.94
Change in Working Capital
0.460.03-4.723.730.20.34
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.